Objective-PAR4 (protease-activated receptor 4), one of the thrombin receptors in human platelets, has emerged as a promising target for the treatment of arterial thrombotic disease. Previous studies implied that thrombin exosite II, known as a binding site for heparin, may be involved in thrombin-induced PAR4 activation. In the present study, a heparin octasaccharide analog containing the thrombin exosite II-binding domain of heparin was chemically synthesized and investigated for anti-PAR4 effect. Approach and Results-PAR4-mediated platelet aggregation was examined using either thrombin in the presence of a PAR1 antagonist or γ-thrombin, which selectively activates PAR4. SCH-28 specifically inhibits PAR4-mediated platelet aggregation, as well as the signaling events downstream of PAR4 in response to thrombin. Moreover, SCH-28 prevents thrombin-induced β-arrestin recruitment to PAR4 but not PAR1 in Chinese Hamster Ovary-K1 cells using a commercial enzymatic complementation assay. Compared with heparin, SCH-28 is more potent in inhibiting PAR4-mediated platelet aggregation but has no significant anticoagulant activity. In an in vitro thrombosis model, SCH-28 reduces thrombus formation under whole blood arterial flow conditions. Conclusions-SCH-28, a synthetic small-molecular and nonanticoagulant heparin analog, inhibits thrombin-induced PAR4 activation by interfering with thrombin exosite II, a mechanism of action distinct from other PAR4 inhibitors that target the receptor. 
T hrombin, the principal enzyme of the blood coagulation cascade, plays a key role in thrombosis and hemostasis. Thrombin not only acts as a coagulation protease but also as a potent stimulator of platelets. Moreover, thrombin-induced platelet aggregation, which is related to arterial thrombotic disease, is relatively refractory to the main antiplatelet drugsaspirin and ADP P2Y 12 (purinergic receptor P2Y 12 ) inhibitors. 1 Therefore, therapeutic strategies focusing on thrombin receptors might offer a more effective treatment for patients resistant to current antiplatelet therapy. 2, 3 Thrombin stimulates human platelets through PAR (protease-activated receptor ) 1 and 4, which belong to the family of G protein-coupled receptors. 4 PAR1 and PAR4 are activated by unmasking of a tethered peptide ligand upon proteolysis of their amino-terminus. PAR1 is a high-affinity thrombin receptor and binds to thrombin exosite I through a hirudin-like domain; PAR4 lacks this domain and has lower affinity for thrombin. PAR1 accounts for platelet activation by low concentrations of thrombin, but PAR4 contributes to signaling at higher concentrations of thrombin. 5 Therefore, blockade of both PARs is needed for effective prevention of high thrombin-induced platelet activation. 6 In addition, there are significant differences in the kinetics of PAR1 and PAR4 signaling. PAR1 mediates a rapid, transient response, whereas PAR4 mediates a slower, sustained signal in response to thrombin. 7, 8 PAR1 is the most investigated thrombin receptor, and a PAR1 antagonist, vorapaxar, has been approved to prevent thrombotic events in patients with a history of myocardial infarction. 9 Although less extensively studied, PAR4 has emerged as a promising target for antiplatelet therapy. 10, 11 Recent studies have shown that specific blockade of PAR4 can provide significant antithrombotic effects with a low bleeding tendency. 12, 13 In our previous study, YD-3 (1-benzyl-3-[ethoxycarbonylphenyl]-indazole), a PAR4 antagonist, 14 synergistically enhanced exosite I inhibitors, but not exosite II inhibitors, to prevent thrombin-induced human platelet aggregation. 15 Furthermore, YD-3 inhibited platelet response to γ-thrombin, which lacks exosite I but preserves exosite II. These results imply a possible link between PAR4 and exosite II. Recently, Boknäs et al 16 reported that blockade of thrombin exosite II with either heparin or HD-22 (5′-AGTCCGTGGTAGGGCAGGTTGGGGTGACT-3′) inhibited PAR4 activation, suggesting a novel strategy to prevent PAR4-mediated platelet response to thrombin.
Heparin, a widely used anticoagulant, is a mixture of sulfated polysaccharides that vary in length and sulfation. 17 Heparin binds to antithrombin via a specific pentasaccharide sequence and catalyzes the inactivation of thrombin as well as factor Xa. For inhibiting thrombin, heparin/antithrombin needs to bind to thrombin exosite II by a regular region (also called thrombin-binding domain) in heparin that is not necessary for Xa inhibition. 18 In contrast to the specific antithrombin-binding pentasaccharide, the thrombin-binding domain consists of repeats of a disaccharide unit of either iduronic acid (IdoA) or glucuronic acid, and glucosamine (GlcN) residues with varying patterns of sulfation. The finding that heparin's anticoagulant activity is mainly attributable to the antithrombin-binding domain has led to development of the synthetic pentasaccharide fondaparinux, which selectively binds to antithrombin and catalyzes the inactivation of factor Xa. 19 In addition to anticoagulant effects, many other bioactivities of heparin have been suggested, including anti-inflammatory and anti-metastatic effects. 20 Notably, these effects appear to be independent on the anticoagulant activity, since they can be caused by heparin preparations or oligosaccharides that lack antithrombin-binding properties. 21, 22 Most of the previous studies, however, used heparin oligosaccharides prepared from enzymatic or chemical digestion of native heparin; by these methods, it is difficult to obtain highly homogenous preparations. Therefore, synthetic heparin oligosaccharides with well-defined configurations are necessary for determining structure−activity relationships.
The structural heterogeneity of heparin is not only relative to its complex pharmacodynamic and pharmacokinetic properties but also to its adverse effects. 18 Synthetic homogenous heparin analogs with well-defined pharmacological activity may provide clinical benefits with less side effects than conventional heparins. 23 Here, we describe the chemical synthesis of a heparin octasaccharide analog containing the thrombin exosite II-binding domain. The molecular weight of the analog, SCH-28 (5-aminopentyl GlcNS (6S)-IdoA(2S)-GlcNS(6S)-IdoA(2S)-GlcNS(6S)-IdoA(2S)-GlcNS(6S)-IdoA(2S); 2765 Da), is much smaller than the average molecular weights of unfractionated heparin (12 000-15 000 Da) and low-molecular-weight heparin (4000-6000 Da). SCH-28 exhibits potent and selective inhibition of PAR4-mediated platelet aggregation without significant anticoagulant activity.
Materials and Methods
The authors declare that all supporting data are available within the article and its online-only Data Supplement.
Materials
RWJ-56110 was purchased from Tocris Bioscience. HD-1 and HD-22 were from Protech Technology. Collagen (equine tendon) for induction of platelet aggregation was purchased from Helena Laboratories. PAR1 agonist peptide (SFLLRN-NH 2 [serine-phenylalanine-leucine-leucine-arginine-asparagine amide]), PAR4 agonist peptide (AYPGKF-NH 2 [alanine-tyrosine-proline-glycine-lysine-phenylalanine amide]), and the peptide GPRP-NH 2 (glycine-proline-arginineproline amide) were purchased from Bachem Bioscience. U46619, the antibodies for phospho-ERK (extracellular signal-regulated kinase; Tyr204), and actin were purchased from Santa Cruz Biotechnology. The antibodies for phospho-Akt (Thr308), phospho-p38 MAPK (mitogen-activated protein kinases) (Thr180/Tyr182), and phospho-(Ser) PKC (protein kinase C) substrates were purchased from Cell Signaling Technology. Human γ-thrombin was from Haematologic Technologies. Fluo-3/AM was purchased from Enzo Life Sciences. Dade Actin FSL activated partial thromboplastin time (APTT) reagent was purchased from Siemens. YD-3 was a kind gift from Prof ShengChu Kuo at China Medical University, Taichung, Taiwan.
Synthesis of SCH-28
The experimental procedures for synthesis of SCH-28 [ 
Preparation of Washed Human Platelet Suspension
Whole blood was collected from healthy human volunteers who had not taken any drugs in the last 2 weeks and mixed with anticoagulant acid citrate dextrose. This study was approved by the Institutional Review Board of Kaohsiung Medical University, and informed consent was acquired from all volunteers. Platelet suspension was prepared according to the washing procedure described previously. 15 The concentration of platelet suspension was adjusted to 3×10 8 platelets/mL in Tyrode's solution (2 mmol/L Ca 
Measurement of Platelet Aggregation
Platelet aggregation was measured using an optical aggregometer (Chrono-Log Co, Havertown, PA) under continuous stirring at 37°C. The extent of platelet aggregation was measured as the maximal increase of light transmission within 5 minutes after the addition of stimulators. In the experiments using γ-thrombin as a stimulator, the exosite I inhibitor HD-1 (1 μmol/L) was added to platelets for inhibition of remaining α-thrombin in the γ-thrombin preparation.
Measurement of Platelet Intracellular Ca 2+ Mobilization
Intracellular Ca 2+ concentrations of platelets were measured according to a previously described method. 24 In brief, platelets separated from platelet-rich plasma were resuspended with Ca -free Tyrode's solution. Extracellular calcium (1 mmol/L) was added to platelets 1 minute before stimulation by agonists. The fluorescence of platelets (Ex 505 nm, Em 530 nm) was monitored with a fluorescence spectrophotometer (Model F4000; Hitachi, Tokyo, Japan). Cytosolic-free calcium concentrations of platelets were calculated by using a K d of 864 nmol/L.
Western Blotting
After treatment, platelets were lysed by adding 2×SDS sample buffer containing 5% β-mercaptoethanol. The samples were boiled for 5 minutes and then stored at −20°C. The platelet lysates were electrophoresed on the SDS polyacrylamide gel and then transferred onto the nitrocellulose membrane. The membrane was blocked with 5% BSA and incubated with primary antibody at 4°C overnight or at room temperature for 2 hours. After washing with Tris-buffered saline/Tween 20, the membrane was incubated with horseradish peroxidase-conjugated secondary antibody at room temperature for 1 hour. After washing, the protein bands were visualized by the Chemiluminescence Western Blot Detection System (Thermo Scientific).
Measurement of PAR4-or PAR1-Mediated β-Arrestin Recruitment in Chinese Hamster
Ovary-K1 Cells PAR4-or PAR1-mediated β-arrestin recruitment was measured in Chinese Hamster Ovary (CHO-K1) PathHunter cells (DiscoveRx, Freemont, CA) stably expressing PAR4 or PAR1 (fused with an enzyme donor fragment of β-gal) and β-arrestin (fused with a β-gal enzyme acceptor). On activation of PAR4 or PAR1, the β-arrestin is recruited to the receptor, resulting in activation of β-gal through complementation of the enzyme fragments. This assay was performed according to the manufacturer's instructions and previous studies. 25, 26 In brief, cells were seeded at 1×10 4 cells/well in a 96-well white polystyrene plate (Thermo/Nunc, Rochester, NY) and cultured at 37°C overnight in growth media (DiscoveRx, Freemont, CA). After replacement of original media by vehicle-or drug-containing media, cells were exposed to thrombin for 45 minutes or PAR-activating peptides for 90 minutes. Detection agent (PathHunter Detection kit) was then added, and luminescent signal was detected after 60 minutes incubation.
Molecular Simulation Study for the Binding of SCH-28 With Thrombin
To investigate the interaction between SCH-28 with thrombin exosite II, a molecular simulation study was performed based on the X-ray crystal structures of thrombin with a bound heparin octasaccharide. 27 Molecular simulation was performed on an Asus personal computer with Intel(R) Core(TM) 2 Quad 2.4 GHz processor, running Windows 7 using Discovery Studio 3.0 (DS 3.0; Discovery Studio Modeling Environment, Accelrys Software Inc, San Diego, 2005-2010). The crystal structure of a thrombin-heparin octasaccharide complex was downloaded from the Protein Data Bank (http://www.rcsb.org/pdb/index.html; PDB code: 1XMN). Since only a heparin-binding site size of 6 saccharide units was shown in 1XMN, 2 saccharide units were manually reconstructed within the DS 3.0 modeling environment to create the crystal structure of thrombin with SCH-28 or an octasaccharide (H8), which is identical to SCH-28 but without a 5-aminophentyl residue at the reducing end. To reduce the complexity, we removed all the surrounding waters. Next, we performed the structural minimization of molecular mechanics by using the CHARMm (Chemistry at Harvard Molecular Mechanics) forcefield. 28 The background coordinates, the first 6 saccharide units of SCH-28 and H8, and nearby thrombin monomers were fixed during the structural optimization. The possible lowest-energy poses of SCH-28 and H8 and their potential energies of reconstructed fragments were illustrated in the UCSF Chimera 1.13 graphics environment. 29 
Measurement of the Activated Partial Thromboplastin Time and Thrombin Time
The APTT and thrombin time (TT) were measured using an automated blood coagulation analyzer (CA-50; Sysmex co, Kobe, Japan). Platelet-poor plasma obtained from sodium citrate-anticoagulated human blood was incubated with vehicle or drugs for 1 minute at 37°C. The APTT reagent (Dade Actin FSL) was added into plasma and incubated for an additional 3 minutes. Finally, CaCl 2 (8.3 mmol/L) was added to initiate the coagulation cascade, and the APTT was determined as the time required to form a fibrin clot. For TT assay, Dade thrombin reagent was used to initiate the coagulation process. The upper limit of detection of APTT or TT was 190 seconds.
Measurement of Whole Blood Thrombus Formation in Flow Chambers
Flow chambers (μ-Slide VI 0.1, ibidi GmbH, Munich, Germany) were coated with Type I collagen from calf skin (Sigma-Aldrich, St Louis) at a concentration 500 μg/mL in the flow chambers for 1 hour at 37°C. Citrated whole blood was incubated with DiOC6(3) 2 μmol/L for 10 minutes at 37°C in the presence of vehicle or drugs. Calcium chloride (5 mmol/L) and magnesium chloride (1.5 mmol/L) were added into the labeled blood immediately before it was perfused through the flow chamber by a syringe pump (KD Scientific Inc, New Hope, PA) for 2 minutes at a wall shear rate of 1500 S −1 (15 dyn/cm 2 ). The channels were then washed with PBS buffer for 2 minutes at the same shear rate to remove nonadherent cells. The adherent platelets were excited by a laser at 488 nm and examined with a confocal laser-scanning microscope (FV1000, Olympus). Stacks of consecutive Z sections of confocal images on an area of 100 698 μm 2 were taken throughout the height of thrombi with a ×40objective at 0.3 μm intervals. The thrombus volume per field of view was calculated as the summation of the surface area covered by a thrombus in each individual confocal section multiplied by height (the z-axis interval 0.3 μm) between adjacent sections, according to a previously reported method.
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Statistics
Results were presented as the mean±SEM. The Shapiro-Wilk test was used to assess the normality of distribution of investigated parameters. Differences between the groups were evaluated with 1-way ANOVA followed by the Bonferroni post hoc test for data normally distributed and with Kruskal-Wallis with Dunn's post hoc test for data not normally distributed. P<0.05 was considered statistically significant.
Results
Design and Synthesis of the Heparin Octasaccharide SCH-28
The most common disaccharide unit in heparin's thrombinbinding domain is IdoA(2S)-GlcNS(6S), 31 where IdoA(2S) represents 2-O-sulfated iduronic acid and GlcNS(6S) represents N-and 6-O-sulfated GlcN. The binding affinity of heparin to thrombin increases with increasing saccharide chain length and negative charges. 32 On the contrary, heparin mimetics containing ≥10 saccharides and >13 sulfate groups have a higher potential to bind platelet factor 4 and to induce thrombocytopenia. 33 Therefore, an octasaccharide containing 4 IdoA(2S)-GlcNS(6S) units was chosen to be synthesized ( Figure 1A ). In addition, the free hydroxyl group at the reducing end of the octasaccharide was substituted with a 5-aminopentyl group. A molecular simulation study of SCH-28 binding to thrombin exosite II predicts that SCH-28 has a lower potential energy than its parent octasaccharide H8 (−150.86 versus −114.92 kcal/mol). This is apparently because of the aminopentyl residue in SCH-28 that forms 2 additional hydrogen bonds to thrombin Leu 130 (leucine 130) and the neighboring saccharide ( Figure 1B ).
SCH-28 Specifically Inhibits PAR4-Mediated Platelet Aggregation
In the present study, we used 2 approaches to investigate PAR4-mediated platelet aggregation. First, thrombin-induced PAR1 activation was blocked by using a PAR1 antagonist, RWJ-56110; in this condition, platelet aggregation in response to thrombin was dependent on PAR4-medicated signaling. 6 Another approach is to use γ-thrombin to activate platelet PAR4. γ-Thrombin is an auto-proteolytic product of thrombin that lacks exosite I and cannot efficiently bind to and activate PAR1. Thus γ-thrombin-induced platelet aggregation only relies on PAR4. 34 As shown in Figure 2A and Figure I in the online-only Data Supplement, blockade of PAR1 alone by RWJ-56110 (10 μmol/L) decreased the rate of onset, but not the extent, of thrombin (0.075 U/mL)-induced human platelet aggregation. In the presence of RWJ-56110, the PAR4 antagonist YD-3 (20 μmol/L) was able to prevent platelet responses to thrombin, indicating that this event is PAR4-dependent. The heparin octasaccharide SCH-28 alone did not affect the onset of platelet aggregation but had a partial inhibitory effect on the extent at the highest concentration tested (2 μmol/L). When in combination with RWJ-56110, SCH-28 (0.2-1 μmol/L) exhibited a similar but more potent effect than YD-3 on inhibiting PAR4-mediated platelet aggregation. On the contrary, the combination of SCH-28 with YD-3 had no additional effect.
In addition, SCH-28 alone potently prevented γ-thrombininduced platelet aggregation with an IC 50 value of 0.19±0.04 μmol/L ( Figure 2B ). This result further supports that SCH-28 is an inhibitor of PAR4-mediated platelet aggregation.
To examine the selectivity of SCH-28, different platelet agonists, including PAR1-activating peptide (10 μmol/L), PAR4-activating peptide (100 μmol/L), the thromboxane A 2 mimetic U46619 (2 μmol/L), and collagen (5 μg/mL) were Figure 1 . Synthesis of the heparin octasaccharide SCH-28. A, The scheme of synthesis of SCH-28. B, Molecular simulation study on SCH-28 binding with thrombin exosite II. The illustration shows the possible lowest-energy configurations of bound SCH-28 or H8, which is identical to SCH-28 but has a hydroxyl group instead of a 5-aminopentyl residue at the reducing end (the right end), in the exosite II of thrombin monomers, AB and GH. The potential energies of the 2 configurations are −150.86 and −114.92 kcal/mol, respectively. The fixed background coordinates, the first 6 saccharide units of SCH-28 and H8, as well as thrombin monomers are semi-transparent in color. Both SCH-28 and H8 can form hydrogen bonds (pointed out by black arrows) to thrombin Arg233, but the aminopentyl residue of SCH-28 forms 2 additional hydrogen bonds to thrombin Leu130 (pointed out by the blue arrow) and the neighboring saccharide (pointed out by the red arrow), respectively. TEMPO indicates (2,2,6,6-tetramethylpiperidin-1-yl)oxyl; BAIB, bis(acetoxy)iodobenzene.
used to elicit platelet aggregation. As shown in Figure 2C , SCH-28 had no effect on platelet response to all these agonists at a concentration of 2 μmol/L.
The finding that SCH-28 failed to inhibit PAR4-activating peptide-induced platelet aggregation suggests that PAR4 is not the direct target of SCH-28. Instead, SCH-28 may prevent thrombin-induced PAR4 activation by interfering with exosite II. This is confirmed by the fact that SCH-28 potentiated an exosite I inhibitor's antiplatelet effect against thrombin but not that of an exosite II inhibitor ( Figure II in the online-only Data Supplement).
SCH-28 Inhibits PAR4-Mediated Signaling During Platelet Activation
We further investigated the effect of SCH-28 on PAR4-mediated signaling, including intracellular Ca 2+ mobilization, PKC, Akt, and mitogen-activated protein kinases ERK, and p38. As shown in Figure 3A , RWJ-56110 and SCH-28 alone reduced thrombin-induced calcium mobilization by 58.9% and 45.3%, respectively, although the combination caused a 77.2% decrease. Western blot assay ( Figure 3B ) revealed that, in thrombin-stimulated platelets, the early-phase activations (1 minute) of PKC (as evident by the phosphorylation of the substrate p47), MAPK, and Akt were more susceptible to RWJ-56110 than SCH-28 ( Figure 3B ). In the late phase (3 minutes), the inhibitory effect of RWJ-56110 on PKC and P38 activation was attenuated, whereas the action of SCH-28 became pronounced. Combination of RWJ-56110 with SCH-28 led to further inhibition of PKC and P38 activation. In addition, SCH-28 also prevented γ-thrombin-induced activation of PKC and MAPK ( Figure 3C ). These results indicate that SCH-28 is effective in preventing PAR4 signaling in human platelets.
SCH-28 Selectively Inhibits Thrombin-Induced PAR4 Activation in CHO-K1 Cells Stably Expressing PAR4
To further confirm the effect and selectivity of SCH-28 on PARs, we used the PathHunter β-arrestin assay system to measure β-arrestin recruitment to the receptors, which is an immediate-early response to G protein-coupled receptor activation. The specificity of PathHunter β-arrestin CHO-K1 cells expressing either PAR4 or PAR1 was validated using selective agonists and antagonists ( Figure III in the online-only Data Supplement). Figure 4 shows that in PAR4-expressing CHO-K1 cells, SCH-28 (0.5-4 μmol/L) concentrationdependently prevented thrombin-elicited β-arrestin recruitment to PAR4. In contrast, SCH-28 had no significant effect on thrombin-induced β-arrestin recruitment to PAR1, even at the highest concentration used. In addition, SCH-28 did not affect PAR4-activating peptide-induced β-arrestin recruitment to PAR4. This was distinct from the putative PAR4 antagonist YD-3, which inhibited PAR4-activating peptideinduced responses.
SCH-28 Exhibits More Potent Anti-PAR4 Effect Than Heparin but With Less Anticoagulant Activity
We would like to compare the effects of SCH-28 and heparin on PAR4-mediated platelet aggregation and on plasma coagulation. Heparin concentration-dependently prevented γ-thrombin-induced platelet aggregation with an IC 50 value of 3.7±0.7 μg/mL that is less potent than SCH-28 ( Figure 5A ).
The anticoagulant activity of SCH-28 and heparin was measured by APTT and TT assays. In human plasma, the control value of APTT and TT was 33.0±0.8 and 18.7±0.6 seconds, respectively. Heparin (0.5-2 μg/mL) concentrationdependently prolonged APTT and TT to above 190 seconds (the upper limit of detection). In contrast, SCH-28 did not significantly affect APTT and TT at concentrations up to 2 μmol/L (Figure 5B and 5C ).
SCH-28 Prevents In Vitro Thrombus Formation in a Flow Chamber
The in vitro antithrombotic effect of SCH-28 was determined by using a collagen-coated chamber with flowing whole blood. The blood was anticoagulated with sodium citrate, labeled with DiO6(3), and recalcified immediately before the blood was perfused through the flow chamber. The shear rate of blood flow in the chamber was 1500 s −1 , which mimics that in arteries. As shown in Figure 6 , platelet adhesion and thrombus formation on collagen-coated surfaces were evident after 2 minutes of blood perfusion. Heparin (2 μg/mL) Figure 2 . SCH-28 specifically inhibits PAR4 (protease-activated receptor 4)-mediated platelet aggregation by thrombin. Washed human platelets were incubated with SCH-28 (0.1-2 µmol/L), RWJ-56110 (RWJ; 10 µmol/L), the PAR4 antagonist YD-3 (1-benzyl-3-(ethoxycarbonylphenyl)-indazole; 20 µmol/L), or their combination at 37°C for 3 minutes, then the platelet aggregation caused by various stimulators (thrombin 0.075 U/mL, γ-thrombin 30 nmol/L, PAR1-AP 10 μmol/L, PAR4-AP 100 μmol/L, U46619 2 μmol/L, or collagen 5 μg/mL) was determined. A, SCH-28 inhibits thrombin-induced platelet aggregation in the presence of the PAR1 antagonist RWJ-56110. B, SCH-28 alone inhibits γ-thrombin-induced platelet aggregation. C, SCH-28 had no effect on platelet aggregation caused by PAR1-activating peptide (PAR1-AP), PAR4-activating peptide (PAR4-AP), U46619, or collagen. Percentages of platelet aggregation are presented as mean±SEM (n=5-6). **P<0.01 as compared with control or the indicated group.
significantly reduced thrombus formation in collagen-coated chambers perfused with recalcified citrated whole blood. This result is similar to that observed by Tourdot et al, 35 suggesting that thrombin-dependent mechanisms are involved in this model. Pretreatment of blood with either RWJ-56110 or SCH-28 resulted in decreases in thrombus volume. Moreover, combined RWJ-56110 with SCH-28 caused further inhibition of thrombus formation.
Discussion
Growing evidence has implicated PAR4 as a potential alternative target to PAR1 for treating thrombotic disease. In comparison with PAR1 that is critical for initial platelet responses to thrombin, PAR4 mediates the late stage of thrombin-induced platelet activation and helps to maintain the stability of platelet aggregation 36, 37 ; therefore, blockade of PAR4 may restrict thrombus propagation in pathological vessels with less interference with the initial thrombus formation and primary hemostasis. 12, 13 In the present study, we have demonstrated that a synthetic heparin octasaccharide analog, SCH-28, specifically inhibits PAR4-mediated platelet aggregation, as well as the signaling events downstream of PAR4 in response to thrombin. Moreover, SCH-28 prevented thrombin-induced β-arrestin recruitment to PAR4 but not PAR1 in CHO-K1 cells using enzymatic complementation assay. Functional and molecular simulation assays reveal that the anti-PAR4 effect of SCH-28 appears to be because of inhibition of thrombin exosite II. Therefore, the mode of action of SCH-28 is distinct from other small-molecule PAR4 inhibitors that target the receptor. The irreversible proteolytic mechanism of PARs activation by thrombin has been a major challenge for development of PARs inhibitors, as they must overcome the endogenous tethered ligands that have a high concentration within the receptors. 9 In addition, platelets expressing a variant in PAR4 Thr120 (threonine 120), which is more common in black subjects than in whites, are more sensitive to PAR4 stimulation and resistant to PAR4 antagonists. 38 Targeting thrombin exosite II thus might provide a useful alternative for PAR4 inhibition.
Thrombin exosite II is known to mediate thrombin binding to platelet GP (glycoprotein) Ibα. 39 Although conflicting, GPIbα has been suggested to be involved in thrombin-induced platelet activation. [40] [41] [42] However, it is unlikely that the anti-PAR4 activity of SCH-28 is because of interference with the thrombin-GPIb interaction. Because γ-thrombin is unable to bind to GPIb 43 and can induce human platelet aggregation in the absence of GPIb, 16 SCH-28 inhibition of γ-thrombin-elicited platelet activation is apparently GPIb-independent.
Heparin is the standard treatment for venous thrombosis. In contrast, platelet-rich arterial thrombosis is relatively resistant to heparin. 44 Heparin can be used in combination with antiplatelet drugs for preventing thrombosis after percutaneous coronary intervention in patients with acute coronary syndrome. 45 However, the risk of bleeding is the major complication associated with heparin therapy. Previous studies have suggested that modified heparins with enhanced antiplatelet activity and reduced anticoagulant activity may be more effective in treating platelet-dominated arterial thrombosis without significant impairment of systemic coagulation. 46 ,47 SCH-28 is more potent than heparin in inhibiting PAR4-mediated platelet activation. On the contrary, SCH-28 exhibits no significant anticoagulant activity because of lack of antithrombin-binding domain sequence. We also show that SCH-28 reduces in vitro thrombus formation under whole blood arterial flow conditions. Therefore, SCH-28 may have potential advantages in the treatment of arterial thrombosis.
In conclusion, SCH-28, a synthetic small-molecular and nonanticoagulant heparin analog, selectively inhibit PAR4-mediated platelet activation and aggregation. The Figure 6 . SCH-28 prevents in vitro thrombus formation in a flow chamber. Platelets in citrated whole blood were labeled with DiOC6(3) 2 μmol/L for 10 min at 37°C in the presence of heparin (2 μg/mL), RWJ-56110 (RWJ; 10 μmol/L) and SCH-28 (0.5 μmol/L). Labeled blood was recalcified immediately before perfusing through a collagen-coated flow chamber (μ-Slide VI 0.1) for 2 min at a wall shear rate of 1500 S −1 (15 dyn/cm 2 ). After then, nonadherent cells were removed by washing with PBS buffer. The images of adherent platelets were recorded with a fluorescent confocal microscope. Representative fluorescent images of platelet thrombi are shown. The volumes of platelet thrombi were quantified as described in Materials and Methods (means±SEM; n=4; *P<0.05 vs control). Comparison of the anti-PAR4 (protease-activated receptor 4) and anticoagulant activities of heparin and SCH-28. A, Heparin inhibits γ-thrombininduced platelet aggregation. Washed human platelets were incubated with heparin (0.2-10 μg/mL) or SCH-28 (0.5 µmol/L) at 37°C for 3 min, then platelet aggregation caused by γ-thrombin (30 nmol/L) was determined (mean±SEM; n=5; *P<0.05 vs control). B and C, Anticoagulant effects of heparin and SCH-28. B, For activated partial thromboplastin time (APTT) assay, human plasma was incubated with SCH-28 or heparin for 1 min, then APTT reagent was added for another 3 min. The coagulation process was trigger by the addition of CaCl 2 (8.3 mmol/L). C, For thrombin time (TT) assay, thrombin reagent was used to trigger plasma clotting as described in Materials and Methods. APTT and TT were determined by using a blood coagulation analyzer, and the upper limit of detection was 190 sec (mean±SEM; n=5 in B and 4 in C; *P<0.05, ***P<0.001 vs control).
characteristics of SCH-28 provide a new strategy for targeting PAR4 with the potential for the treatment of arterial thrombosis.
